HCC Clinical Studies
Hepatocellular carcinoma (HCC) is the world's sixth most commonly-diagnosed cancer and the second-leading cause of cancer deaths annually.
Unfortunately, for patients with advanced HCC who are ineligible for liver transplant, surgery or radio-frequency ablation, and have failed to respond after multiple courses of transarterial chemotherapy (TACE), few proven treatments exist.
A series of three large clinical trials which evaluated the effect of SIR-Spheres® Y-90 resin microspheres in advanced HCC has recently reported results:
- SARAH and SIRveNIB compared head to head SIR-Spheres Y-90 resin microspheres with sorafenib. The studies did not demonstrate a significant difference in survival, but showed that SIR-Spheres Y-90 resin microspheres were significantly better tolerated and lead to substantially increased tumour response rates compared to sorafenib.1,2
- SORAMIC examined the effect of treating advanced HCC patients initially with SIR-Spheres Y-90 resin microspheres before initiating sorafenib versus sorafenib alone. While no significant improvement in Overall Survival was shown for the whole cohort, specific patient sub-groups seem to benefit from the addition of SIR-Spheres Y-90 resin microspheres.3
1. Vilgrain V et al. Lancet Oncol 2017; 18: 1624–1636.
2. Chow PKH et al. J Clin Oncol 2018; 36: 1913-1921.
3. Ricke J et al. J Hepatol 2019; 71: 1164-1174.
